Sarepta Therapeutics Inc
NASDAQ: SRPT
$114.32
-$3.52 (-3.0%)
Closing Price on November 12, 2024
SRPT Articles
Wednesday’s top analyst upgrades, downgrades and initiations included AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor and Wynn Resorts,
Published:
Last Updated:
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
Published:
Last Updated:
Considering the new Trump administration, there is an increasingly positive sentiment in the health care sector. In the past year, the health care sector was in trouble under fire from congressional...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone and Sarepta.
Published:
Last Updated:
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm and Xilinx.
Published:
Last Updated:
Shares of Summit Therapeutics more than doubled on Tuesday after it was announced that it would be entering into a licensing deal with Sarepta Therapeutics.
Published:
Last Updated:
Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood out from the rest with at least 25% gains.
Published:
Last Updated:
Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.
Published:
Last Updated:
Making the move for a secondary offering after a stock has jumped massively is one way for companies to literally cash in on their recent success.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include American Electric Power, Broadcom, Ford, General Motors, JD.com, Sarepta Therapeutics and Valeant Pharmaceuticals.
Published:
Last Updated:
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, AT&T, Autodesk, Bluebird Bio, Monsanto and Sarepta Therapeutics.
Published:
Last Updated:
Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy.
Published:
Last Updated:
These four biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the past year, offering aggressive accounts the best entry points in some time.
Published:
Last Updated: